A proof-of Concept, Randomized 3-month Study to Evaluate the Effects of Three Contraceptive Intrauterine Systems Delivering Copper and a Daily Dose of 5, 20 or 40 μg of Ulipristal Acetate (UPA)

NCT03230539 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Contraception

Interventions

DRUG: Ulipristal Acetate IUS delivering Cu and 5μg
DRUG: Ulipristal Acetate IUS delivering Cu and 20μg
DRUG: Ulipristal Acetate IUS delivering Cu and 40μg

Sponsor

Population Council